August 29, 2011 | Less than 1% of cancer patients participate in a clinical trial, according to a study published in the September issue of the Annals of Surgery. 

eCliniqua | A new type of clinical trial now undergoing testing at the Veterans Affairs (VA) Boston Healthcare System will likely be of interest to emerging accountable care organizations (ACOs) as well as the drug companies that court them. The new approach, most useful in comparative effectiveness research, overcomes the chief disadvantages of the two flanking options: an observational study involving non-experimental treatment decision making or a full-scale, randomized and placebo-controlled trial. 

By eCliniqua Staff August 4, 2011 | ClearTrial, maker of clinical trial operations software for planning and budgeting trials, released results of a survey earlier this week assessing how life sciences professionals forecast and budget for clinical trials. Almost half of the

eCliniqua | On Wednesday, one day after the FDA issued a letter accusing CRO Cetero of "significant violations" at a Cetero facility in Houston, the company responded in a letter on its website.  

July 18, 2011 | The Michael J. Fox Foundation for Parkinson's Research has launched a Web-based solution to connect patients with Parkinson's Disease clinical trials. The beta version of the Fox Trial Finder (www.foxtrialfinder.org) compares volunteer information such as location and medical history with trial eligibility requirements to find the best potential matches at study sites nearby. The service matches both people with Parkinson's and control volunteers with the trials that need them.   

By Ann Neuer  July 13, 2011 | CHICAGO—This year’s annual DIA meeting featured hundreds of exhibitors and session topics ranging from patient recruitment to cloud computing to improving regulatory reporting. There were several overriding themes including the continuing march towards

Jun 3 | Guest Commentary | Interim analyses offer companies the opportunity to stop studies early when it appears the primary objective will not be achieved or halt trials when there is clear evidence that the primary objective has already been met. This not only lowers costs but also speeds up the time to develop the compound, which obviously benefits both the company and patients.